Akèy › Neuroblastom › Massachusetts › Boston
Etid klinik pou Neuroblastom nan Boston, MA
13 etid pou Neuroblastom ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Ap rekriteFaz 3
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
MCT for the Harvard/UCSF ROBIN Center
Ap rekrite
- Brigham and Women's Hospital, Boston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute ( Site 1013), Boston
B7-H3.CD28Z.CART in Solid Tumors
Ap rekriteFaz 1
- Dana Farber Cancer Institite, Boston
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Ap rekriteFaz 3
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
SPEARHEAD-3 Pediatric Study
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Ap rekriteFaz 1/2
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Ap rekriteFaz 2
- Boston Children's Hospital, Dana-Farber Cancer Institute., Boston
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Ap rekriteFaz 1
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Neuroblastoma Biology Study
Ap rekriteEtid obsèvasyon
- Children's Hospital Boston, Boston
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
Ap rekrite
- Dana-Farber Cancer Institute, Boston
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Ap rekriteFaz 1/2
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Etid Neuroblastom nan lòt vil
- Washington, DC11 etid
- New York City, NY10 etid
- Dallas, TX9 etid
- Memphis, TN9 etid
- Philadelphia, PA9 etid
- St. Louis, MO9 etid
- Aurora, CO8 etid
- Hartford, CT8 etid
- Minneapolis, MN8 etid
- Birmingham, AL8 etid
- Atlanta, GA7 etid
- San Francisco, CA7 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.